Antiphospholipid antibody syndrome: New insights on thrombogenic mechanisms

American Journal of the Medical Sciences

Volumn 316, Issue 2, 1998, Pages 142-151

  Rand, Jacob H ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Annexin V; Anticardiolipin antibodies; Antiphospholipid syndrome; Lupus anticoagulant; Thrombosis

Indexed keywords

ANNEXIN; LUPUS ANTICOAGULANT;

ANTIBODY DETECTION; ANTICOAGULATION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIGENICITY; ANTIPHOSPHOLIPID SYNDROME; COMPLEX FORMATION; CONFERENCE PAPER; HUMAN; ICOSANOID METABOLISM; THROMBOGENESIS; THROMBOSIS;

EID: 0031856150     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199808000-00009     Document Type: Conference Paper

References (108)

1. Hughes GRV. The anticardiolipin syndrome. Clin Exp Rheumatol. 1985;3:285-6.
2. Harris EN, Hughes GRV, Gharav AE. The antiphospholipid antibody syndrome. J Rheumatol. 1987;suppl13:210.
3. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med. 1994;96: 3-9.
4. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med. 1997;157:2101-8.
5. Asherson RA, Cervera R, Piette J-C, Shoenfeld Y, eds. The Antiphospholipid Syndrome. Boca Raton, FL: CRC Press; 1996.
6. Hughes GRV, Khamashta MA, Gharavi AE, Wilson WA, eds. Lupus. Special Issue, 7th International Symposium on Antiphospholipid Antibodies. New Orleans: Stockton Press; 1996.
7. Moore JE, Mohr CF. Biologically false positive serological tests for syphilis: type, incidence, and cause. J Am Med Assoc. 1952;150:467-73.
8. Moore JE, Lutz WB. Natural history of systemic lupus erythematosus: approach to its study through chronic biologic false positive reactors. J Chronic Dis. 1955;1:297-316.
9. Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb. 1982;6:263-85.
10. Bell WN, Alton HG. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature. 1954;174:880.
11. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. In: Spaet TH, ed. Progress in Hemostasis and Thrombosis. New York: Grune & Stratton; 1972:75.
12. Bowie WEJ, Thompson JH, Pascuzzi CA, Owen GA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Clin Invest. 1963;62:416-30.
13. Laurell A, Nilsson I. Hypergammaglobulinemia, circulating anticoagulant and biologic false-positive Wassermann reaction. J Lab Clin Med. 1957;49:694.
14. Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity: mechanism of a lupus anticoagulant. J Clin Invest. 1980;66:397-405.
15. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2:1211-4.
16. Bick RL, Baker WF. Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost. 1994;20:3-15.
17. Piette JC. 1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a "mission impossible"? Lupus. 1996;5:354-63.
18. Alarcon Segovia D, et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum. 1992;21:275-86.
19. Rauch J, Janoff AS. Antibodies against phospholipid other than cardiolipin: potential roles for both phospholipid and protein. Lupus. 1996;5:498-502.
20. Berard M, Chantome R, Marcelli A, Boffa MC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol. 1996;23:1369-74.
21. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril. 1996;66:540-6.
22. de Maistre E, Gobert B, Bene MC, Briquel ME, Lecompte T, Faure GC. Comparative assessment of phospholipid-binding antibodies indicates limited overlapping. J Clin Lab Anal. 1996;10:6-12.
23. Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol. 1997;89(4):549-55.
24. Laroche P, Berard M, Rouquette AM, Desgruelle C, Boffa MC. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol. 1996;106:549-54.
25. Garcia CO, Kanbour Shakir A, Tang H, Molina JE, Espinoza LR, Gharavi AE. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. Am J Reprod Immunol. 1997;37:118-24.
26. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 1985;313:1322-6.
27. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, et al. Immunization with anticardiolipin cofactor (beta-2- glycoprotein-I) induces experimental anti-phospholipid syndrome in naive mice. J Autoimmun. 1994;7:441-55.
28. Krause I, Blank M, Gilbrut B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol. 1993;29:155-61.
29. Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus. 1996;5:451-5.
30. Pierangeli SS, Barker JH, Stilkovac D, Ackerman D, Anderson G, Barquinero J, et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 1994;71:670-4.
31. Olee T, Pierangeli SS, Handley HH, Le DT, Wei X, Lai C, et al. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A. 1996;93:8606-11.
32. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20:231-6.
33. Vila P, Hernandez MC, Lopez Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72:209-13.
34. Jones JV, Eastwood BJ, Jones E, James H, Mansour M. Antiphospholipid antibodies in a healthy population: methods for estimating the distribution. J Rheumatol. 1995;22:55-61.
35. Ginsberg JS, Wells PS, Brill-Edwards P. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-91.
36. Lockwood CJ, Rand JH. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv. 1994;49:432-41.
37. Zangari M, Lockwood CJ, Scher J, Rand JH. Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies. Thromb Res. 1997;85:177-83.
38. The antiphospholipid antibodies and stroke study group (APASS). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology. 1997;48:91-4.
39. Reverter J, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol. 1996;16:1319-26.
40. Finazzi G. The Italian Registry of antiphospholipid antibodies. Haematologica. 1997;82:101-5.
41. Casciola Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1996;93:1624-9.
42. Price BE, Rauch J, Shia MA, Walsh MT, Lieberthal W, Gilligan HM, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol. 1996;157:2201-8.
43. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544-7.
44. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4.
45. Chonn A, Semple SC, Cullis PR. Beta 2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem. 1995;270:25845-9.
46. Goldsmith GH, Pierangeli SS, Branch DW, Gharavi AE, Harris EN. Inhibition of prothrombin activation by antiphospholipid antibodies and beta(2)-glycoprotein 1. Br J Haematol. 1994;87:548-54.
47. Hunt J, Krilis S. The fifth domain of beta(2)-glycoprotein-I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol. 1994;152:653-9.
48. Matsuura E. Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on beta 2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus. 1995;4:S13-S17.
49. Roubey RA, Pratt CW, Buyon JP, Winfleld JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest. 1992;90:1100-4.
50. Najmey SS, Keil LB, Abid DY, Debari VA. The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: a meta-analysis. Ann Clin Lab Sci. 1997;27:41-6.
51. Ogasawara M, Aoki K, Matsuura E, Sasa H, Yagami Y. Anti beta 2 glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance. Lupus. 1996;5:587-92.
52. Falcon CR, Martinuzzo ME, Forastiero RR, Cerrato GS, Carreras LO. Pregnancy loss and autoantibodies against phospholipid-binding proteins. Obstet Gynecol. 1997;89:975-80.
53. Cabral AR, Amigo MC, Cabiedes J, Alarcon Segovia D. The antiphospholipid/cofactor syndrome: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med. 1996;101:472-81.
54. Cabiedes J, Cabral AR, Alarcon Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol. 1995;22:1899-1906.
55. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost. 1996;75:721-4.
56. de Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus. 1996;5:488-93.
57. Shibata S, Harpel PC, Gharavi A, Rand JH, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood. 1994;83(9):2532-40.
58. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize beta(2)-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol. 1995;154:954-60.
59. Alarcon Segovia D, Cabrai AR. The concept and classification of antiphospholipid/cofactor syndrome. Lupus. 1996;5:364-7.
60. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986;13:486-9.
61. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med. 1996;47:533-53.
62. Triplett DA. Lupus anticoagulant/antiphospholipid antibodies: the great imposters. Lupus. 1996;5:431-5.
63. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161:369-73.
64. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996;76:916-24.
65. Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RFA. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol. 1993;83:466-72.
66. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997;127:177-85.
67. Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum. 1996;25:414-20.
68. Goldstein R, Moulds JM, Smith CD, Sengar DP. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol. 1996;23:1173-9.
69. Manco Johnson MJ, Nuss R, Key N, Moertel C, Jacobson L, Meech S, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr. 1996;128:319-23.
70. Prieto J, Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology. 1996;23:199-204.
71. Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patient with human Parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 1997;40:103-8.
72. Eschwege V, Freyssinet JM. The possible contribution of cell apoptosis and necrosis to the generation of phospholipid-binding antibodies. Ann Med Interne Paris. 1996; 147(suppl1):33-5.
73. Lin YL, Wang CT. Activation of human platelets by rabbit anticardiolipin antibodies. Blood. 1992;80:3135-43.
74. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood. 1991;78:2894-9.
75. Kaaja R, Julkunen H, Viinikka L, Ylikorkala O. Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin. Obstet Gynecol. 1993;81:327-31.
76. Hasselaar P, Derksen RH, Blokzijl L, de Groot PG. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemost. 1988;59:80-5.
77. Schinco PC, Marranca D, Bazzan M, Borchiellini A, Fantino A, Garis G, et al. Lupus anticoagulant: interference with in vivo prostaglandin production and with platelet sensitivity to prostacyclin. Scand J Rheumatol. 1992; 21:124-8.
78. Dueymes M, Levy Y, Ziporen L, Jamin C, Piette JC, Shoenfeld Y, et al. Do some antiphospholipid antibodies target endothelial cells? Ann Med Interne Paris. 1996;147(suppl1):22-3.
79. Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40:551-61.
80. Matsuda J, Gotoh M, Kawasugi K, Tsukamoto M, Saitoh N. Anti-endothelial cell antibodies to the endothelial hybridoma cell line (EAhy926) in systemic lupus erythematosus patients with antiphospholipid antibodies. Br J Haematol. 1997;97:227-32.
81. Navarro M, Cervera R, Teixido M, Reverter JC, Font J, Lopez Soto A, et al. Antibodies to endothelial cells and to beta 2-glycoprotein I in the antiphospholipid syndrome: prevalence and isotype distribution. Br J Rheumatol. 1996;35:523-8.
82. Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate endothelial cells. Lupus. 1996;5:440-1.
83. Meroni PL, Papa ND, Beltrami B, Tincani A, Balestrieri G, Krilis SA. Modulation of endothelial cell function by antiphospholipid antibodies. Lupus. 1996;5:448-50.
84. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol. 1993;168:206-10.
85. Etches WS, Gordon PA. Detection of antiphospholipid antibody-dependent C5b-9 formation. Lupus. 1996;5:514.
86. Arfors L, Lefvert AK. Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti-phospholipid syndrome (APLS). Clin Exp Immunol. 1997;108:47-51.
87. Martini F, Farsi A, Gori AM, Boddi M, Fedi S, Domeneghetti MP, et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus. 1996;5:206-11.
88. Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies: a crucial role for acquired free protein S deficiency. Thromb Haemost. 1996;76:190-4.
89. Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost. 1996;76:689-91.
90. Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras LO. Activated protein C resistance in patients with anti-beta 2-glycoprotein I antibodies. Blood Coagul Fibrinol. 1996;7:702-4.
91. Vaarala O, Puurunen M, Lukka M, Alfthan G, Leirisalo Repo M, Aho K, et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol. 1996;104:269-74.
92. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 1996;98:815-25.
93. Witztum JL, Horkko S. The role of oxidized LDL in atherogenesis: immunological response and anti-phospholipid antibodies. Ann N Y Acad Sci. 1997;811:88-96: discussion:96-9.
94. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus. 1996;5:442-7.
95. Andree HAM, Hermens WT, Hemker HC, Willems GM. Displacement of factor Va by annexin V. In: Andree HAM, ed. Phospholipid Binding and Anticoagulant Action of Annexin V. Maastricht, The Netherlands: Universitaire pers Maastricht; 1992:73-85.
96. Tait JF, Sakata M, McMullen BA, Miao CH, Funakoshi T, Hendrickson LE, et al. Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family. Biochemistry. 1988;27:6268-76.
97. Reutelingsperger CPM, Kop JM, Hornstra G, Hemker HC. Purification and characterization of a novel protein from bovine aorta that inhibits coagulation: inhibition of the phospholipid-dependent factor-Xa-catalyzed prothrombin activation, through a high-affinity binding of the anticoagulant to the phospholipids. Eur J Biochem. 1988;173:171-8.
98. Creutz CE. The annexins and exocytosis. Science. 1992;258:924-31.
99. Morgan RO, Fernandez MP. Molecular phylogeny of annexins and identification of a primitive homologue in Giardia lamblia. Mol Biol Evol. 1995;12:967-79.
100. Morgan RO, Pilar Fernandez M. Distinct annexin subfamilies in plants and protists diverged prior to animal annexins and from a common ancestor. J Mol Evol. 1997;44:178-88.
101. Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol. 1992;22:1-14.
102. Krikun G, Lockwood CJ, Wu XX, Zhou X, Guller S, Calandri C, et al. The expression of annexin V (placental anticoagulant protein-I) by villous trophoblasts: immunolocalization and in vitro regulation. Placenta. 1994;15:601-12.
103. Vogt E, Ng A, Rote NS. Antiphosphatidylserine antibody removes annexin V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am J Obstet Gynecol. 1997;177:964-72.
104. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets: evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem. 1990;265:17420-3.
105. Rand JH, Wu X, Andree HAM, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med. 1997;337:154-60.
106. Flaherty MJ, West S, Heimark RL, Fujikawa K, Tait JF. Placental anticoagulant protein-I: measurement in extracellular fluids and cells of the hemostatic system. J Lab Clin Med. 1990;115:174-81.
107. Rand JH, Wu X, Guller S, Gil J, Scher J, Lockwood CJ. Reduction of annexin2-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol. 1994;171:1566-72.
108. Rand JH, Wu X, Guller S, Scher J, Andree HAM, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol. 1997;177:918-23.